Trial Profile
A Phase I Study in Patients With Peritoneal Carcinomatosis Using SCH 58500 (rAd/p53) Administered by Single Intraperitoneal Instillation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Contusugene ladenovec (Primary)
- Indications Peritoneal cancer
- Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics
- Sponsors Merck & Co
- 08 Jul 2014 New trial record